Drug intelligence / Profile preview

Jianpi prescription chewable tablets

Development stage: Unknown
Lead developer: Shuguang Hospital
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Jianpi prescription chewable tablets is a compound traditional Chinese medicine (TCM) formulation developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is designed to address "spleen deficiency" (TCM Jianpi) and is primarily indicated for the treatment of musculoskeletal conditions in older adults, including dysmotility syndrome, sarcopenia, and osteoporosis. The formulation is often evaluated in combination with exercise therapy to improve musculoskeletal function and quality of life.

Other names: Jianpi prescriptionJianpi chewable tablets

Beyond the preview

Go deeper on Jianpi prescription chewable tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jianpi prescription chewable tablets.

Explore the full profile